Sign In
Buy BIOA
$16.04
-0.500 (-3.02%)
At Close: Jun 03, 2026
This IPO Biotech Stock Could Be the Next Eli Lilly
09:05am, Thursday, 03'rd Oct 2024
BioAge has its eyes on a handful of truly gargantuan markets.
RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic
BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival
12:36pm, Monday, 30'th Sep 2024
The biotech sector is reviving, with IPOs reappearing and BioAge Labs' weight loss drug, Azelaprag, showing market potential. Biotech stocks are volatile, facing challenges like regulatory hurdles and
U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up
01:00am, Saturday, 28'th Sep 2024
Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Four IPOs and two SPACs submitted initial filings this past week. Six IPOs are currently scheduled to list in the
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
01:18pm, Thursday, 26'th Sep 2024
BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.
BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy
12:26pm, Thursday, 26'th Sep 2024
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
08:31am, Thursday, 26'th Sep 2024
BioAge Labs is having its initial public offering today. The drug developer's signature product, Azelaprag, isn't yet on sale, but it is undergoing clinical trials in hopes it will one day be.
Natural-gas producer BKV and drug-developer BioAge queue up IPOs
08:01am, Thursday, 26'th Sep 2024
Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead of trading.
Weight-loss drug developer BioAge raises $198 mln in U.S. IPO
08:29pm, Wednesday, 25'th Sep 2024
BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the range at $18 per share, the weight-loss drug developer said on Wednesday.
